Clinical Manifestations of ITP in Children

  • Yukihiro TakahashiEmail author


Most cases of idiopathic thrombocytopenic immune thrombocytopenia purpura (ITP) in children occur before 5 years old, show spontaneous remission under careful observation, and resolve with the use of first-line treatments such as steroids or high-dose immunoglobulin. ITP often develops after viral or bacterial infection, or after vaccination. Severe bleeding symptoms and severe thrombocytopenia (<20 × 109/L) are rare but often become refractory. Second-line treatments such as rituximab and thrombopoietin receptor agonists have recently been used for ITP in children, in place of splenectomy. An objective ITP-bleeding assessment score seems necessary for management guidelines and selection of objective treatment in the future.


Immune Thrombocytopenic Purpura Platelet Production International Working Group Bleeding Symptom Antiplatelet Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951;38:1–10.PubMedGoogle Scholar
  2. 2.
    Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008.CrossRefPubMedGoogle Scholar
  3. 3.
    Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definition in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systemic review of the literature. Haematologica. 2008;93:98–103.CrossRefPubMedGoogle Scholar
  4. 4.
    Rodeghiero F, Stasi R, Germheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.CrossRefPubMedGoogle Scholar
  6. 6.
    Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA, American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–207.CrossRefPubMedGoogle Scholar
  7. 7.
    Heitink-Polle KMJ, Nijsten J, Boonacker CWB, de Haas M, Bruin MCA. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014;124:3295–307.CrossRefPubMedGoogle Scholar
  8. 8.
    Nomura S. Advances in diagnosis and treatments for immune thrombocytopenia. Clin Med Insights Blood Disord. 2016;9:15–21.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghia U. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol. 2006;84:48–53.CrossRefPubMedGoogle Scholar
  10. 10.
    Matsubara K, Takahashi Y, Hayakawa A, Tanaka F, Nakadate H, Sakai M, Maeda N, Oka T, Ishii E, Besso F, Morimoto T, Goto H, Hashii Y, Hatakeyama N, Shirahata A, Imaizumi M. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Int J Hematol. 2014;99:429–36.CrossRefPubMedGoogle Scholar
  11. 11.
    Ay Y, Karapinar TH, Oymak Y, Toret E, Demirag B, Ince D, Ozcan E, Moueminoglou N, Koker SA, Vergin C. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura. Blood Coagul Fibrinolysis. 2016;27:431–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118:28–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Garzon AM, Mitchell WB. Use of thrombopoietin receptor agonists in children immune thrombocytopenia. Front Pediatr. 2015; doi: 10.3389/fped.2015.00070.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Burness CB, Keating GM, Garnock-Jones KP. Eltrombopag: a review in paediatric chronic immune thrombocytopenia. Drugs. 2016;76:869–78.CrossRefPubMedGoogle Scholar
  15. 15.
    Elgebaly AS, Ashal GE, Elfil M, Menshawy A. Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials. Clin Appl Thromb Hemost. 2016; pii: 1076029616663849. [Epub ahead of print].Google Scholar
  16. 16.
    Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF, Pediatric ITP Consortium of North America (ICON). Thrombopoietin receptor agonist use in children: data from the Pediatric ITP Consortium of North America ICON2 study. Pediatr Blood Cancer. 2016;63:1407–13.CrossRefPubMedGoogle Scholar
  17. 17.
    McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000;37:239–48.CrossRefPubMedGoogle Scholar
  18. 18.
    Talaat RM, Elmaghraby AM, Barakat SS, El-Shahat M. Alterations in immune cell subjects and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). Clin Exp Immunol. 2014;176:291–300.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kuwana M, Okazaki Y, Kajihara M, Kaburaki J, Miyazaki H, Kawakami Y, Ikeda Y. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum. 2002;46:2148–59.CrossRefPubMedGoogle Scholar
  20. 20.
    Nujum ZT, Thomas A, Vijayakumar K, Nair RR, Pillai MR, Indu PS, Sundar S, Gopakumar S, Mohan D, Sudheeshkumar TK. Comparative performance of the probable case definitions of dengue by WHO (2009) and the WHO-SEAR expert group (2011). Pathog Glob Health. 2014;108:103–10.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85:174–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Yamada H, Kato EH, Kobashi G, Kishida T, Ebina Y, Kaneuchi M, Suzuki S, Fujimoto S. Passive immune thrombocytopenia in neonates of mothers with idiopathic thrombocytopenic purpura: incidence and risk factors. Semin Thromb Hemost. 1999;25:491–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Miura T, Mimaya J, Ishii E, Fujisawa K, Ohta S, Taki M, Imaizumi M, Oka T, Kajiwara M, Kitazawa J, Kubota Y, Takahashi Y, Bessho F, Shirahata A. A nationwide survey of childhood idiopathic thrombocytopenic purpura in 2006. J Pediatr Hematol Oncol. 2008;22:378–81. (in Japanese)Google Scholar
  24. 24.
    Kitazawa J, Miura T, Shirahata A, Takahashi Y, Ishii E, Imaizumi M, Ohta S, Oka T, Kajiwara M, Kubota Y, Taki M, Fujisawa K, Bessho R, Mimaya J. Idiopathic thrombocytopenic purpura following vaccinations. J Pediatr Hematol Oncol. 2008;22:382–4. (in Japanese)Google Scholar
  25. 25.
    Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, Cines DB, Cooper N, Godeau B, Greinacher A, Imbach P, Khellaf M, Klaassen RJ, Kühne T, Liebman H, Mazzucconi MG, Newland A, Pabinger I, Tosetto A, Stasi R. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013;121:2596–606.CrossRefPubMedGoogle Scholar
  26. 26.
    Neunert CE, Buchanan GR, Imbach P, Bolton-Mggs PB, Bennet CM, Neufeld E, Vesely SK, Adix L, Blanchette VS, Kuhne T, for the Intercontinental Cooperative ITP Study Group Registry II Participants. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from Intercontinental Cooperative ITP Study Group (ICIS). Blood. 2013;121:4457–62.CrossRefPubMedGoogle Scholar
  27. 27.
    Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood. 2009;114:4777–83.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Pediatr Hematol Oncol. 1984;6:355–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr. 2002;141:683–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B, Gent M. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993;123:989–95.CrossRefPubMedGoogle Scholar
  31. 31.
    Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet. 1997;350(9078):620–3.CrossRefPubMedGoogle Scholar
  32. 32.
    Koreth R, Weinert C, Weidorf DJ, Key NS. Measurement of bleeding severity: a critical review. Transfusion. 2004;44(4):605–17.CrossRefPubMedGoogle Scholar
  33. 33.
    Shirahata A, Ishii E, Eguchi H, Okawa H, Ohta S, Kaneko T, Konishi S, Sako M, Sekine I, Takahashi Y, Taki M, Tsuchiya S, Fujisawa K, Bessho F, Horikoshi Y, Mimaya J, Akatsuka J, Miyazaki S, ITP Committee of the Japanese Society of Pediatric Hematology. Consensus guideline for diagnosis and treatment of childhood idiopathic thrombocytopenic purpura. Int J Hematol. 2006;83:29–38.CrossRefPubMedGoogle Scholar
  34. 34.
    Sasahara Y, Ouchi M, Imaizumi M. Recent advances in the diagnosis and molecular pathogenesis of congenital thrombocytopenia with small or normal-size platelets. JJPHO. 2013;50:186–91. (in Japanese)Google Scholar
  35. 35.
    Kunishima S. Differential diagnosis of congenital thrombocytopenia with large-side platelets. JJPHO. 2013;50:186–91. (in Japanese)Google Scholar
  36. 36.
    Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998;133:334–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Kühne T, Imbach P, Bolton-Maggs PH, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358:2122–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Fujisawa K, Iyori H, Ohkawa H, Konishi S, Bessho F, Shirahata A, Miyazaki S, Akatsuka J, Japanese Study Group on Childhood ITP. A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol. 2000;72:376–83.PubMedGoogle Scholar
  39. 39.
    Brito HS, Braga JA, Loggetto SR, Machado RS, Granato CF, Kawakami E. Helicobacter pylori infection & immune thrombocytopenic purpura in children and adolescents: a randomized controlled trial. Platelets. 2015;26:336–41.CrossRefPubMedGoogle Scholar
  40. 40.
    Russo G, Miraglia V, Branciforte F, Matarese SM, Zecca M, Bisogno G, Parodi E, Amendola G, Giordano P, Jankovic M, Corti A, Nardi M, Farruggia P, Battisti L, Baronci C, Palazzi G, Tucci F, Ceppi S, Nobili B, Ramenghi U, De Mattia D, Notarangelo L, AIEOP-ITP Study Group. Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study. Pediatr Blood Cancer. 2011;56:273–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Yamazaki T, Shibuya A, Ishii S, Miura N, Ohtake A, Sasaki N, Araki R, Ota Y, Fujiwara M, Miyajima Y, Uetake K, Hamahata K, Kato K, Kawakami K, Toyoda H, Moriguchi N, Okada M, Nishi M, Ogata Y, Takimoto T, Ohga S, Ohta S, Amemiya S. High-dose Cepharanthine for pediatric chronic immune thrombocytopenia in Japan. Pediatr Int. 2016; doi: 10.1111/ped.13151 [Epub ahead of print].
  42. 42.
    Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32:875–87.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.Nara Medical UniversityKashiharaJapan
  2. 2.Japanese Red Cross Nara Blood CenterYamato KoriyamaJapan

Personalised recommendations